Tag Archive for: STAMPEDE trial
Fracture Risk in Prostate Cancer: Insights from a STAMPEDE Trial Analysis on ADT and Zoledronic Acid
/0 Comments/in Retrospective studies/by MaxMetformin and Prostate Cancer: A Review of STAMPEDE Trial from The Lancet
/0 Comments/in Review/by MaxRethinking Treatment for mHSPC: Insights from Dr. Karim Fizazi
/0 Comments/in Expert Insights, Observational, Retrospective studies/by MaxMetformin Shows Promise in Reducing Side Effects of Hormone Therapy in Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor personalized medicine Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial theranostics
Latest Posts
- IND Required for ITC-6146RO for Solid Tumors Overexpressing the B7-H3 Protein September 2, 2025
- Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer August 30, 2025
- Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN) August 29, 2025
- Phase 1: AMG 509 (Xaluritamig) for Metastatic Hormone Sensitive Prostate Cancer August 29, 2025